BR112014032501A2 - composto, e, composição farmacêutica. - Google Patents
composto, e, composição farmacêutica.Info
- Publication number
- BR112014032501A2 BR112014032501A2 BR112014032501A BR112014032501A BR112014032501A2 BR 112014032501 A2 BR112014032501 A2 BR 112014032501A2 BR 112014032501 A BR112014032501 A BR 112014032501A BR 112014032501 A BR112014032501 A BR 112014032501A BR 112014032501 A2 BR112014032501 A2 BR 112014032501A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261664288P | 2012-06-26 | 2012-06-26 | |
DKPA201270369 | 2012-06-26 | ||
PCT/EP2013/063194 WO2014001282A1 (en) | 2012-06-26 | 2013-06-25 | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014032501A2 true BR112014032501A2 (pt) | 2017-06-27 |
Family
ID=49782300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014032501A BR112014032501A2 (pt) | 2012-06-26 | 2013-06-25 | composto, e, composição farmacêutica. |
Country Status (13)
Country | Link |
---|---|
US (2) | US9475797B2 (pt) |
EP (1) | EP2885290B1 (pt) |
JP (1) | JP6223443B2 (pt) |
KR (1) | KR20150033679A (pt) |
CN (1) | CN104411703A (pt) |
AU (1) | AU2013283488A1 (pt) |
BR (1) | BR112014032501A2 (pt) |
CA (1) | CA2876780A1 (pt) |
IL (1) | IL235991A (pt) |
IN (1) | IN2014DN11027A (pt) |
MX (1) | MX2014014872A (pt) |
RU (1) | RU2014149123A (pt) |
WO (1) | WO2014001282A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物 |
JP2023525130A (ja) * | 2020-05-13 | 2023-06-14 | エフ. ホフマン-ラ ロシュ アーゲー | Gaba a alpha5 pamとしての新規トリアゾリル誘導体 |
HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69627195T2 (de) | 1995-11-01 | 2004-01-29 | Novartis Ag | Purinderivate und verfahren zu ihrer herstellung |
FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
AU1724499A (en) | 1997-12-22 | 1999-07-12 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
WO2001044259A1 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
US7115589B2 (en) | 1999-12-17 | 2006-10-03 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
DE60028253T2 (de) | 1999-12-17 | 2007-03-08 | Ariad Pharmaceuticals, Inc., Cambridge | Neue purine |
DE60205376T2 (de) | 2001-06-27 | 2006-04-06 | Cyclacel Ltd. | 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten |
US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
US7262176B2 (en) | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
EP1578722A4 (en) | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
US20030229105A1 (en) | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
MXPA06001758A (es) | 2003-08-15 | 2006-08-11 | Irm Llc | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. |
WO2005067546A2 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
GB0407723D0 (en) | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
FR2876583B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0505219D0 (en) | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
AU2006224605B2 (en) | 2005-03-14 | 2012-03-01 | Aniona Aps | Potassium channel modulating agents and their medical use |
US20090036475A1 (en) | 2005-03-22 | 2009-02-05 | Neurosearch A/S | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
EP1881991A1 (en) | 2005-05-19 | 2008-01-30 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
ES2314943T3 (es) | 2005-09-19 | 2009-03-16 | F. Hoffmann-La Roche Ag | Derivados de isoxazolo como agonistas inversos de gaba a alfa. |
BRPI0617306A2 (pt) | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de isoxazol |
CA2628667A1 (en) | 2005-11-09 | 2007-05-18 | F. Hoffmann-La Roche Ag | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives |
US20090306102A1 (en) | 2005-12-20 | 2009-12-10 | Eriksen Birgitte L | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases |
EP1968972B1 (en) | 2005-12-23 | 2012-11-28 | F. Hoffmann-La Roche AG | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
ATE537171T1 (de) | 2005-12-27 | 2011-12-15 | Hoffmann La Roche | Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e |
ES2371935T3 (es) | 2005-12-27 | 2012-01-11 | F. Hoffmann-La Roche Ag | Derivados de aril-isoxazol-4-il-imidazol. |
BRPI0711875A2 (pt) * | 2006-05-24 | 2012-01-10 | Lilly Co Eli | compostos e métodos para modular os fxr |
CA2651857A1 (en) | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
US20110144140A1 (en) | 2006-09-07 | 2011-06-16 | Eriksen Birgitte L | Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents |
AU2007304195A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
CN101622001A (zh) | 2007-01-26 | 2010-01-06 | Irm责任有限公司 | 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物 |
EP2114916A2 (en) | 2007-02-02 | 2009-11-11 | NeuroSearch A/S | Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
JP2010522720A (ja) | 2007-03-28 | 2010-07-08 | ノイロサーチ アクティーゼルスカブ | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
WO2008116911A1 (en) | 2007-03-28 | 2008-10-02 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
EP2170873B1 (en) | 2007-06-22 | 2011-08-10 | F. Hoffmann-La Roche AG | Isoxazole-imidazole derivatives |
AU2008313789A1 (en) | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine AL receptor ligands |
US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
WO2009071476A1 (en) | 2007-12-04 | 2009-06-11 | F. Hoffmann-La Roche Ag | Isoxazolo-pyridine derivatives |
US7618973B2 (en) | 2007-12-04 | 2009-11-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
PE20110067A1 (es) * | 2008-06-19 | 2011-02-18 | Takeda Pharmaceutical | Derivados de piperidina como inhibidores de renina |
WO2010034706A1 (en) | 2008-09-26 | 2010-04-01 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
US8268838B2 (en) | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
CA2760597C (en) | 2009-05-05 | 2017-08-22 | F. Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
CA2759598C (en) | 2009-05-05 | 2017-09-12 | F. Hoffmann-La Roche Ag | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders |
JP5460858B2 (ja) | 2009-05-05 | 2014-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | イソオキサゾール−ピラゾール誘導体 |
JP5466292B2 (ja) | 2009-05-05 | 2014-04-09 | エフ.ホフマン−ラ ロシュ アーゲー | イソオキサゾール−ピリジン誘導体 |
EP2427457B1 (en) | 2009-05-07 | 2013-07-17 | F.Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as gaba modulators |
EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
ES2536667T3 (es) * | 2010-11-09 | 2015-05-27 | F. Hoffmann-La Roche Ag | Derivados de triazol como ligandos de receptores Gaba |
US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
US8466181B2 (en) | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
-
2013
- 2013-06-25 IN IN11027DEN2014 patent/IN2014DN11027A/en unknown
- 2013-06-25 WO PCT/EP2013/063194 patent/WO2014001282A1/en active Application Filing
- 2013-06-25 AU AU2013283488A patent/AU2013283488A1/en not_active Abandoned
- 2013-06-25 KR KR20157001895A patent/KR20150033679A/ko not_active Application Discontinuation
- 2013-06-25 EP EP13730899.5A patent/EP2885290B1/en active Active
- 2013-06-25 CN CN201380034072.1A patent/CN104411703A/zh active Pending
- 2013-06-25 JP JP2015519035A patent/JP6223443B2/ja active Active
- 2013-06-25 CA CA2876780A patent/CA2876780A1/en not_active Abandoned
- 2013-06-25 MX MX2014014872A patent/MX2014014872A/es unknown
- 2013-06-25 US US14/411,326 patent/US9475797B2/en active Active
- 2013-06-25 BR BR112014032501A patent/BR112014032501A2/pt not_active IP Right Cessation
- 2013-06-25 RU RU2014149123A patent/RU2014149123A/ru not_active Application Discontinuation
-
2014
- 2014-11-30 IL IL235991A patent/IL235991A/en not_active IP Right Cessation
-
2016
- 2016-10-11 US US15/290,480 patent/US9884848B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2014014872A (es) | 2015-08-06 |
EP2885290A1 (en) | 2015-06-24 |
US9884848B2 (en) | 2018-02-06 |
IL235991A (en) | 2017-07-31 |
KR20150033679A (ko) | 2015-04-01 |
RU2014149123A (ru) | 2016-08-20 |
AU2013283488A1 (en) | 2015-01-15 |
US20170114045A1 (en) | 2017-04-27 |
IL235991A0 (en) | 2015-02-01 |
EP2885290B1 (en) | 2017-10-18 |
JP2015521643A (ja) | 2015-07-30 |
CN104411703A (zh) | 2015-03-11 |
CA2876780A1 (en) | 2014-01-03 |
IN2014DN11027A (pt) | 2015-09-25 |
JP6223443B2 (ja) | 2017-11-01 |
WO2014001282A1 (en) | 2014-01-03 |
US9475797B2 (en) | 2016-10-25 |
US20160115155A1 (en) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
BR112014030278A2 (pt) | anticorpo, e, composição. | |
BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
BR112015004233A2 (pt) | inalador. | |
DK3043778T3 (da) | Farmaceutiske sammensætninger, der indeholder refametinib | |
BR112013019327A2 (pt) | composto, e, composição. | |
BR112015004230A2 (pt) | inalador. | |
BR112014032488A2 (pt) | embalagem, e blanqueta | |
BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
BR112013019281A8 (pt) | composições pesticidas. | |
BR112014009950A2 (pt) | composto dissubstituído, compostos e composição farmacêutica | |
BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. | |
BR112014027814A2 (pt) | agentes sinérgicos antimicrobianos. | |
DK2897594T3 (da) | Farmaceutisk sammensætning | |
BR112014028921A2 (pt) | injetor. | |
CL2014003283A1 (es) | Formulación farmacéutica. | |
BR112015010797A2 (pt) | compostos aniônicos substituídos, e, composição farmacêutica | |
BR112013030897A2 (pt) | composição. | |
FR2986872B1 (fr) | . | |
BR112013031544A2 (pt) | composição tópica. | |
BR112014028443A2 (pt) | composição estéril. | |
BR112015002979A2 (pt) | forma cristalina, e, composição farmacêutica | |
BR112015002646A2 (pt) | composto e composição farmacêutica | |
BR112014032501A2 (pt) | composto, e, composição farmacêutica. | |
BR112014016122A2 (pt) | composto, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2520 DE 25/04/2019. |